Bionyra Pharma

French tech company | Builders Republic

About

Clinical-stage biotech company developing next-generation mono- and multispecific antibodies for immune-mediated inflammatory diseases — targeting TL1A (IBD and related indications) and IL-25 (atopic dermatitis, Type 2 inflammation), with half-life-extension (HLE) technology to improve dosing versus existing biologics.

Key facts

Status
Active
Sectors
Healthcare & Life Sciences
Latest stage
Series A
Founded
2025
City
PARIS
Region
IDF
Legal name
BIONYRA PHARMA
SIREN
990995334
Tracked rounds
1
Amount raised
143 M€ raised since 2020

Funding rounds

  • Series A — 2026

Investors